Login to Your Account



Spherix Soars on D-tagatose Results, Starts Partner Hunt

By Jennifer Boggs


Friday, October 8, 2010
Spherix Inc. said its D-tagatose, a product originally developed as a reduced-calorie sugar substitute, hit statistical significance in a Phase III trial in Type II diabetes, news that sent shares of the Bethesda, Md.-based firm up 33 percent in early trading. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription